CA209-9DJ trial: what clinicians have said so far
A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy
- NCT03520491 ↗
- Active, not recruiting
- Memorial Sloan Kettering Cancer Center
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on CA209-9DJ (nivolumab; nivolumab plus ipilimumab in cisplatin-ineligible muscle-invasive bladder cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CA209-9DJ so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Pilot Study to Evaluate the Safety of Neoadjuvant Nivolumab Alone or in Combination With Ipilimumab for Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (CA209-9DJ)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Bladder Cancer
- Interventions
- Nivolumab; Ipilimumab; Radical cystectomy
- Arms
- Cohort 1 · Experimental
- Cohort 2 · Experimental
- Cohort 3 · Experimental
- Cohort U (UTUC patients) is independent from Cohorts 1 - 3. ( who are cisplatin-ineligible) · Experimental
- Enrollment
- 52
- Primary outcomes
- number of patients who proceed to radical cystectomy and pelvic lymph node dissection (RC-PLND)
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 25, 2018
- Primary completion
- Jan 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03520491 · updated Feb 17, 2026
Publications
linked from the registry- Giannakodimos I, Ziogou A, Giannakodimos A, Tzelepis K, Kratiras Z, Fragkiadis E, Zachos I, Tzortzis V, Chrisofos M, Charalampakis N. Neoadjuvant immunotherapy for muscle-invasive bladder cancer: a 2025 update. Immunotherapy. 2025 Apr;17(6):447-455. doi: 10.1080/1750743X.2025.2501929. Epub 2025 May 6. PubMed 40329651